Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alessa Pardo is active.

Publication


Featured researches published by Alessa Pardo.


Theranostics | 2014

Absorption reconstruction improves biodistribution assessment of fluorescent nanoprobes using hybrid fluorescence-mediated tomography.

Felix Gremse; Benjamin Theek; Sijumon Kunjachan; Wiltrud Lederle; Alessa Pardo; Stefan Barth; Twan Lammers; Uwe Naumann; Fabian Kiessling

Aim: Fluorescence-mediated tomography (FMT) holds potential for accelerating diagnostic and theranostic drug development. However, for proper quantitative fluorescence reconstruction, knowledge on optical scattering and absorption, which are highly heterogeneous in different (mouse) tissues, is required. We here describe methods to assess these parameters using co-registered micro Computed Tomography (µCT) data and nonlinear whole-animal absorption reconstruction, and evaluate their importance for assessment of the biodistribution and target site accumulation of fluorophore-labeled drug delivery systems. Methods: Besides phantoms with varying degrees of absorption, mice bearing A431 tumors were imaged 15 min and 48 h after i.v. injection of a fluorophore-labeled polymeric drug carrier (pHPMA-Dy750) using µCT-FMT. The outer shape of mice and a scattering map were derived using automated segmentation of the µCT data. Furthermore, a 3D absorption map was reconstructed from the trans-illumination data. We determined the absorption of five interactively segmented regions (heart, liver, kidney, muscle, tumor). Since blood is the main near-infrared absorber in vivo, the absorption was also estimated from the relative blood volume (rBV), determined by contrast-enhanced µCT. We compared the reconstructed absorption with the rBV-based values and analyzed the effect of using the absorption map on the fluorescence reconstruction. Results: Phantom experiments demonstrated that absorption reconstruction is possible and necessary for quantitative fluorescence reconstruction. In vivo, the reconstructed absorption showed high values in strongly blood-perfused organs such as the heart, liver and kidney. The absorption values correlated strongly with the rBV-based absorption values, confirming the accuracy of the absorption reconstruction. Usage of homogenous absorption instead of the reconstructed absorption map resulted in reduced values in the heart, liver and kidney, by factors of 3.5, 2.1 and 1.4, respectively. For muscle and subcutaneous tumors, which have a much lower rBV and absorption, absorption reconstruction was less important. Conclusion: Quantitative whole-animal absorption reconstruction is possible and can be validated in vivo using the rBV. Usage of an absorption map is important when quantitatively assessing the biodistribution of fluorescently labeled drugs and drug delivery systems, to avoid a systematic underestimation of fluorescence in strongly absorbing organs, such as the heart, liver and kidney.


Cancer Immunology, Immunotherapy | 2012

In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model

Alessa Pardo; Michael Stöcker; Florian Kampmeier; Georg Melmer; Rainer Fischer; Theo Thepen; Stefan Barth

PurposePreclinical in vivo analyses of treatment responses are an important prerequisite to evaluate new therapeutics. Molecular in vivo imaging in the far red (FR)/near infra red (NIR) is a promising method, as it enables measurements at different time points in individual animals, thereby reducing the number of animals required, while increasing statistical significance. Here, we show the establishment of a method to monitor response to treatment using fluorescent cells, expressing the epidermal growth factor receptor (EGFR), a target already used in therapy.MethodsWe transfected A-431 tumour cells with the far red–emitting protein Katushka (Kat2), resulting in strong fluorescence allowing for the monitoring of tumour growth when implanted in BALB/c nu/nu mice with a CRi Maestro in vivo imager. We targeted A-431 cells with a previously reported immunotoxin (IT), consisting of the anti-EGFR antibody single-chain variable fragment (scFv) 425, fused to Pseudomonasaeruginosa Exotoxin A’ (ETA’). In addition, EGFR expression was verified using the 425(scFv) conjugated to a NIR dye BG-747 through a SNAP-tag linker.ResultsThe results show the feasibility to evaluate response to treatment in vivo by FR imaging, while at the same location detecting EGFR expression. Treatment with 425(scFv)-ETA’ resulted in decelerated tumour growth, while not affecting the overall health of the animals. This is in contrast to treatment with Doxorubicin, which, although decreasing the tumour size, resulted in poor health.ConclusionsWe developed a novel method to non-invasively determine treatment responses by in vivo imaging of multiple parameters which showed the efficacy of 425(scFv)-ETA’.


Protein Expression and Purification | 2008

Eukaryotic expression and secretion of EGFP-labeled annexin A5

Michael Stöcker; Alessa Pardo; Christian Hetzel; Chris Reutelingsperger; Rainer Fischer; Stefan Barth

The Ca2+-dependent binding of annexin A5 to phosphatidylserine on cell surfaces is a reliable marker for apoptosis that is widely used in flow cytometry based apoptosis assays. In this approach, annexin A5 must be coupled to a fluorescent dye, but standard dyes such as fluorescein are photolabile, and the heterogeneous chemical linkage partially inhibits binding to phosphatidylserine. Recombinant fusions comprising annexin A5 and fluorescent proteins are available for prokaryotic expression, but can be purified only at low concentrations due to their low solubility in the cytoplasm. Here we describe a eukaryotic expression system for the secretion of functional recombinant annexin A5, with and without fluorescent protein fusions, in different formats. Metal affinity purification yielded up to 18 microg of histidine-tagged annexin A5 fusions per ml processed cell culture supernatants. Furthermore the supernatant itself was sufficient for direct use in apoptosis assays. The availability of such fusion proteins offers new and more economical opportunities for the development and application of this widely utilized apoptosis assay.


Current Pharmaceutical Design | 2013

SNAP-tag based agents for preclinical in vitro imaging in malignant diseases.

Manal Amoury; Tobias Blume; Hannes Brehm; Judith Niesen; Niklas Tenhaef; Stefan Barth; Stefan Gattenlöhner; Wijnand Helfrich; Jenny Fitting; Thomas Nachreiner; Alessa Pardo

Although current cancer treatment strategies are highly aggressive, they are often not effective enough to destroy the collectivity of malignant cells. The residual tumor cells that survived the first-line treatment may continue to proliferate or even metastasize. Therefore, the development of novel more effective strategies to specifically eliminate also single cancer cells is urgently needed. In this respect, the development of antibody-based therapeutics, in particular example immunotoxins, has attracted broad interest. Since the internalization of immunotoxins is essential for their cytotoxic effectivity, it is of crucial importance to study their internalization behavior to assess the potential for their therapeutic use. In this study, we determined the internalization behavior of four different single-chain fragments variable (scFv) when binding to the corresponding target antigen as expressed on solid or non-solid tumor cell lines. The scFvs were recombinantly fused to the SNAP-tag, an engineered variant of the human repair enzyme O(6)-alkylguanine-DNA alkyltransferase that covalently reacts with benzylguanine derivatives. Since a large number of highly sensitive organic fluorescent dyes are already available or can easily be derivatized to react with the self-labeling SNAP-tag, this system provides versatile applications for imaging of intraand extracellular compartments of living cells. The fusion proteins were coupled to SNAP-surface(®) Alexa Fluor(®) 488 or SNAP-surface(®) Alexa Fluor(®) 647 and binding as well as internalization was monitored by flow cytometry and confocal microscopy, respectively. Depending on the respective target antigen, we could distinguish between slow and rapid internalization behavior. Moreover, we detected increased internalization rate for bivalent scFv constructs. Our approach allows for rapid and early stage evaluation of the internalization characteristics of new antibodies designated for further therapeutic development.


Current Pharmaceutical Design | 2013

SNAP-Tag Technology: A General Introduction

Katharina Kolberg; Christiane Puettmann; Alessa Pardo; Jenny Fitting; Stefan Barth

Over the past few years, the SNAP-tag technology has become a methodology with great potential in a variety of applications, e.g. the (specific) visualization of individual proteins and studies of protein interaction in living cells. Furthermore, the tag can be used for immunopurification and detection of recombinant proteins or site-specific coupling of recombinant proteins to surfaces. Next to the in vitro applications, it also enables detection of tagged proteins in vivo. This review gives an overview of the SNAP-tag technology in different fields of research and its potential for future developments.


International Journal of Cancer | 2016

A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.

Manal Amoury; Radoslav Mladenov; Thomas Nachreiner; Anh-Tuan Pham; Dmitrij Hristodorov; Stefano Di Fiore; Wijnand Helfrich; Alessa Pardo; Georg H. Fey; Michael Schwenkert; Theophilus Thepen; Fabian Kiessling; Ahmad Fawzi Hussain; Rainer Fischer; Katharina Kolberg; Stefan Barth

Chondroitin sulfate proteoglycan 4 (CSPG4) has been identified as a highly promising target antigen for immunotherapy of triple‐negative breast cancer (TNBC). TNBC represents a highly aggressive heterogeneous group of tumors lacking expression of estrogen, progesterone and human epidermal growth factor receptor 2. TNBC is particularly prevalent among young premenopausal women. No suitable targeted therapies are currently available and therefore, novel agents for the targeted elimination of TNBC are urgently needed. Here, we present a novel cytolytic fusion protein (CFP), designated αCSPG4(scFv)‐MAP, that consists of a high affinity CSPG4‐specific single‐chain antibody fragment (scFv) genetically fused to a functionally enhanced form of the human microtubule‐associated protein (MAP) tau. Our data indicate that αCSPG4(scFv)‐MAP efficiently targets CSPG4+ TNBC‐derived cell lines MDA‐MB‐231 and Hs 578T and potently inhibits their growth with IC50 values of ∼200 nM. Treatment with αCSPG(scFv)‐MAP resulted in induction of the mitochondrial stress pathway by activation of caspase‐9 as well as endonuclease G translocation to the nucleus, while induction of the caspase‐3 apoptosis pathway was not detectable. Importantly, in vivo studies in mice bearing human breast cancer xenografts revealed efficient targeting to and accumulation of αCSPG4(scFv)‐MAP at tumor sites resulting in prominent tumor regression. Taken together, this preclinical proof of concept study confirms the potential clinical value of αCSPG4(scFv)‐MAP as a novel targeted approach for the elimination of CSPG4‐positive TNBC.


Cancer Letters | 2016

Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.

Manal Amoury; Katharina Kolberg; Anh-Tuan Pham; Dmitrij Hristodorov; Radoslav Mladenov; Stefano Di Fiore; Wijnand Helfrich; Fabian Kiessling; Rainer Fischer; Alessa Pardo; Theophilus Thepen; Ahmad Fawzi Hussain; Thomas Nachreiner; Stefan Barth

Triple-negative breast cancer (TNBC) is associated with poor prognosis and high prevalence among young premenopausal women. Unlike in other breast cancer subtypes, no targeted therapy is currently available. Overexpression of epithelial cell adhesion molecule (EpCAM) in 60% of TNBC tumors correlates with poorer prognosis and is associated with cancer stem cell phenotype. Thus, selective elimination of EpCAM(+) TNBC tumor cells is of clinical importance. Therefore, we constructed a fully human targeted cytolytic fusion protein, designated GbR201K-αEpCAM(scFv), in which an EpCAM-selective single-chain antibody fragment (scFv) is genetically fused to a granzyme B (Gb) mutant with reduced sensitivity to its natural inhibitor serpin B9. In vitro studies confirmed its specific binding, internalization and cytotoxicity toward a panel of EpCAM-expressing TNBC cells. Biodistribution kinetics and tumor-targeting efficacy using MDA-MB-468 cells in a human TNBC xenograft model in mice revealed selective accumulation of GbR201K-αEpCAM(scFv) in the tumors after i.v. injection. Moreover, treatment of tumor-bearing mice demonstrated a prominent inhibition of tumor growth of up to 50 % in this proof-of-concept study. Taken together, our results indicate that GbR201K-αEpCAM(scFv) is a promising novel targeted therapeutic for the treatment of TNBC.


Cancer Letters | 2015

Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion protein

Hannes Brehm; Dmitrij Hristodorov; Alessa Pardo; Radoslav Mladenov; Judith Niesen; Rainer Fischer; Mehmet Kemal Tur; Stefan Barth

The treatment of rhabdomyosarcoma (RMS) is challenging, and the prognosis remains especially poor for high-grade RMS with metastasis. The conventional treatment of RMS is based on multi-agent chemotherapy combined with resection and radiotherapy, which are often marked by low success rate. Alternative therapeutic options include the combination of standard treatments with immunotherapy. We generated a microtubule-associated protein (MAP)-based fully human cytolytic fusion protein (hCFP) targeting the fetal acetylcholine receptor, which is expressed on RMS cells. We were able to express and purify functional scFv35-MAP from Escherichia coli cells. Moreover, we found that scFv35-MAP is rapidly internalized by target cells after binding its receptor, and exhibits specific cytotoxicity toward FL-OH1 and RD cells in vitro. We also confirmed that scFv35-MAP induces apoptosis in FL-OH1 and RD cells. The in vivo potential of scFv35-MAP will need to be considered in further studies.


Journal of Cancer Research and Clinical Oncology | 2017

Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer

Claudia Kessler; Alessa Pardo; Mehmet Kemal Tur; Stefan Gattenlöhner; Rainer Fischer; Katharina Kolberg; Stefan Barth

PurposeDespite great progress in the diagnosis and treatment of localized prostate cancer (PCa), there remains a need for new diagnostic markers that can accurately distinguish indolent and aggressive variants. One promising approach is the antibody-based targeting of prostate stem cell antigen (PSCA), which is frequently overexpressed in PCa. Here, we show the construction of a molecular imaging probe comprising a humanized scFv fragment recognizing PSCA genetically fused to an engineered version of the human DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (AGT), the SNAP-tag, enabling specific covalent coupling to various fluorophores for diagnosis of PCa. Furthermore, the recombinant immunotoxin (IT) PSCA(scFv)-ETA′ comprising the PSCA(scFv) and a truncated version of Pseudomonas exotoxin A (PE, ETA′) was generated.MethodsWe analyzed the specific binding and internalization behavior of the molecular imaging probe PSCA(scFv)-SNAP in vitro by flow cytometry and live cell imaging, compared to the corresponding IT PSCA(scFv)-ETA′. The cytotoxic activity of PSCA(scFv)-ETA′ was tested using cell viability assays. Specific binding was confirmed on formalin-fixed paraffin-embedded tissue specimen of early and advanced PCa.ResultsAlexa Fluor® 647 labeling of PSCA(scFv)-SNAP confirmed selective binding to PSCA, leading to rapid internalization into the target cells. The recombinant IT PSCA(scFv)-ETA′ showed selective binding leading to internalization and efficient elimination of target cells.ConclusionsOur data demonstrate, for the first time, the specific binding, internalization, and cytotoxicity of a scFv-based fusion protein targeting PSCA. Immunohistochemical staining confirmed the specific ex vivo binding to primary PCa material.


Molecular Cancer Therapeutics | 2013

Abstract B240: Novel protein fusion toxins targeting c-kit positive neuroendocrine tumors.

Swati Choudhary; Alessa Pardo; Reinhard Rosinke; Stefan Barth; Janendra K. Batra; Rama S. Verma

Currently, the treatment options for patients with neuroendocrine carcinomas (NECs) are limited. Stem cell factor is found to have a trophic role in neuroendocrine cancer cells through an autocrine growth loop, which leads to the activation of the c-kit receptor. NECs like neuroblastomas, small cell lung carcinomas and poorly differentiated human colon carcinoma cells (CRCs) over-express both the c-kit receptor and its ligand, stem cell factor (SCF), as compared to normal cells. The role of the known c-kit inhibitor imatinib has already been investigated in these cell types and has shown promising results. We developed SCF-based c-kit targeting protein fusion toxins against neuroendocrine carcinomas, such as neuroblastomas and colorectal carcinomas. In this study, SCF was cloned from the HepG2 cell line and mutated in order to optimize its expression. The mutated SCF was recombinantly fused with bacterial toxins (Diphtheria toxin (DT) and Pseudomonas exotoxin A (PE)) to form c-kit targeting fusion toxins. These proteins were expressed in E.coli and purified by affinity chromatography followed by size exclusion chromatography. Flow cytometric analysis was used to monitor receptor expression on c-kit positive neuroblastoma cell lines (IMR 32 and SHSY5Y), colon carcinoma cell lines (HT-29, HCT 116 and DLD-1), and the c-kit negative cell line, MCF-7. In vitro binding, internalization and toxicity studies were performed on the above cell lines in order to characterize the purified chimeric toxins. Annexin V binding assays and cell cycle analysis were performed additionally, to prove their efficacy. The ID50 values for the toxins were found to correlate with the receptor expression on these cell lines. The novel c-kit targeting protein fusion toxins reported in our study offer a promising strategy for therapeutics against neuroendocrine tumors and warrant further testing in such tumors with c-kit autocrine and paracrine loops. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B240. Citation Format: Swati Choudhary, Alessa Pardo, Reinhard Rosinke, Stefan Barth, Janendra K. Batra, Rama S. Verma. Novel protein fusion toxins targeting c-kit positive neuroendocrine tumors. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B240.

Collaboration


Dive into the Alessa Pardo's collaboration.

Top Co-Authors

Avatar

Stefan Barth

University of Cape Town

View shared research outputs
Top Co-Authors

Avatar

Rainer Fischer

Pharmaceutical Product Development

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Wijnand Helfrich

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Rainer Fischer

Pharmaceutical Product Development

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge